Russell Investments Group
PHAT icon

Russell Investments Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Russell Investments Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$952K Buy
85,683
+79,039
+1,190% +$998K ﹤0.01% 2237
2025
Q4 		$110K Buy
6,644
+282
+4% +$4.03K ﹤0.01% 3024
2025
Q3 		$74.9K Buy
6,362
+3,626
+133% +$37.4K ﹤0.01% 3128
2025
Q2 		$26.2K Sell
2,736
-39,063
-93% -$216K ﹤0.01% 3133
2025
Q1 		$262K Buy
+41,799
New +$254K ﹤0.01% 2511
2024
Q4 		– Sell
-36
Closed -$651 – 3770
2024
Q3 		$651 Sell
36
-484
-93% -$6.76K ﹤0.01% 3534
2024
Q2 		$5.36K Buy
+520
New +$5.36K ﹤0.01% 3197
2024
Q1 		– Sell
-39,292
Closed -$359K – 3352
2023
Q4 		$359K Buy
39,292
+25,172
+178% +$217K ﹤0.01% 2315
2023
Q3 		$146K Buy
14,120
+5,139
+57% +$70.5K ﹤0.01% 2548
2023
Q2 		$129K Buy
+8,981
New +$104K ﹤0.01% 2554
2022
Q2 		– Sell
-575
Closed -$7K – 2951
2022
Q1 		$7K Sell
575
-8,788
-94% -$142K ﹤0.01% 2724
2021
Q4 		$183K Sell
9,363
-3,123
-25% -$73.5K ﹤0.01% 2740
2021
Q3 		$400K Sell
12,486
-190
-1% -$6.31K ﹤0.01% 2553
2021
Q2 		$428K Buy
+12,676
New +$454K ﹤0.01% 2661

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Russell Investments Group's PHAT Position: Q1 2026 in Review

Russell Investments Group increased its Phathom Pharmaceuticals (PHAT) stake by 1,190% in Q1 2026, buying an estimated $998K and bringing the position to 85,683 shares worth $952K. The position accounts for ﹤0.01% of the portfolio, ranked #2237.

Russell Investments Group first reported a position in PHAT in Q2 2021 and has held it in 14 quarters since. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Russell Investments Group held 85,683 shares of Phathom Pharmaceuticals worth $952K as of Q1 2026.
  • Russell Investments Group bought 79,039 Phathom Pharmaceuticals shares in Q1 2026, an estimated $998K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2237 holding.
  • Russell Investments Group first reported a position in Phathom Pharmaceuticals in Q2 2021 and has held it in 14 quarters since.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.